MOLECULARHEALTH
DEAD

Serial Number

85583345

Owner

Molecular Health GmbH

Attorney

Nicole E. Gage

Filing Date

Mar 29, 2012

Add to watchlist:

No watchlists yet
View on USPTO

MOLECULARHEALTH Trademark

Serial Number: 85583345 • Registration: 4710227

MOLECULARHEALTH is a trademark filed by Molecular Health GmbH on March 29, 2012. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

Molecular Health GmbH (44 trademarks)

Belfortstr. 2
Heidelberg 69115 , DE

Entity Type: 03

Molecular Health AG (6 trademarks)

Dufourstr. 25
4010 Basel , CH

Entity Type: 99

Trademark Details

Filing Date

March 29, 2012

Registration Date

March 31, 2015

Published for Opposition

July 1, 2014

Cancellation Date

November 19, 2021

Goods & Services

Data collection services for business purposes, namely, the collection and systematic sorting of clinical and patient data comprising patient specific molecular and/or genomic data, patient specific clinical data and scientific clinical studies; data collection services for business purposes, namely, the collection of mathematic and statistical data, clinical data, patient data and data of clinical studies relating to clinical response to drug treatments; data and text processing services, namely, the processing of patient specific information, molecular test results and clinical studies data via computer

Providing an online database featuring medical, pharmaceutical and genomic information for medical diagnostic or treatment purposes; pharmaceutical consulting services in pharmaceuticals and genetics in relation to patient medical treatment options; medical consulting services with respect to the treatment and diagnosis of individuals in the fields of clinical pharmacology and the analysis of dose-effect relationships for treatment purposes; providing pharmaceutical information, namely, information about drug safety and drug compatibility in relation to cancer therapy and the treatment of individual patients; medical consulting services in the fields of patient treatment and treatment protocols; medical consulting services in the field of pharmaceuticals and genetics, namely, conducting drug safety and dosage assessment and in drug compatibility studies in the field of cancer treatment therapy for others

Data collection for medical and scientific research purposes, namely, the collection and systematic sorting of clinical and patient data comprising patient specific molecular and/or genomic data, patient specific clinical data and scientific clinical studies; data collection for medical and scientific research purposes, namely, the collection of mathematic and statistical data, clinical data, patient data and data of clinical studies relating to clinical response to drug treatments; compiling data for research purposes in the field of medical science, namely, compiling patient specific molecular and genomic data, patient specific clinical data and scientific clinical studies; scientific, technical and research services for medical purposes in the field of medical diagnostic and treatment research; providing medical and scientific research information and scientific consulting in the fields of pharmaceutical side effects, genomics, biological medicine and translational medicine; providing an online database comprised of medical, pharmaceutical, biological and genomic information for scientific research purposes; providing an online searchable database in the fields of medical, pharmaceutical, biological, clinical and genomic information for scientific research purposes; providing an online searchable database in the fields of biological medical, translational medicine, interventional epidemiology, bioinformatics, clinical information technology, genomic data and genomic sequence analysis for scientific research purposes; design and development of computer software in the fields of biology, medicine, and bioinformatics; design and development of computer software for integration of patient specific data, molecular test results, clinical studies and scientific results; providing online non-downloadable computer software for use by healthcare professionals for medical diagnostic and treatment research; design and development of databases featuring biomarker data; providing an online searchable database for clinical and scientific research in the field of medical, diagnostic and treatment research; Software as a Service (SAAS) services featuring software for providing information for patient treatment by enabling the retrieval and correlation of genomic data, drug protocols, clinical profiling and integration and statistical analysis of data for medical purposes; providing online non-downloadable software for retrieval and correlation of genomic data, drug protocols, clinical profiling and integration and statistical analysis of data for medical diagnostic and treatment research purposes; medical research and scientific research and scientific consulting services, namely, designing and conducting drug safety and dosage assessment and drug compatibility studies in the field of cancer therapy for others

Filing History

CANCELLED SEC. 8 (6-YR)
Nov 19, 2021 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Mar 31, 2020 REM1
REGISTERED-PRINCIPAL REGISTER
Mar 31, 2015 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Feb 26, 2015 DP1B
NOTICE OF ALLOWANCE CANCELLED
Feb 26, 2015 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Feb 24, 2015 D1BR
NOA MAILED - SOU REQUIRED FROM APPLICANT
Aug 28, 2014 NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 26, 2014 NOAM
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Aug 20, 2014 ASCK
NOTICE OF PUBLICATION
Jul 2, 2014 NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 1, 2014 NPUB
PUBLISHED FOR OPPOSITION
Jul 1, 2014 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 11, 2014 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
May 23, 2014 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
May 22, 2014 CNSA
EXAMINER'S AMENDMENT ENTERED
May 15, 2014 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 15, 2014 GNEN
EXAMINERS AMENDMENT E-MAILED
May 15, 2014 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 15, 2014 CNEA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Apr 24, 2014 GPRN
PRIORITY ACTION E-MAILED
Apr 24, 2014 GPRA
PRIORITY ACTION WRITTEN
Apr 24, 2014 CPRA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 20, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 20, 2014 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Mar 14, 2014 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Sep 25, 2013 GNS2
INQUIRY TO SUSPENSION E-MAILED
Sep 25, 2013 GNSI
SUSPENSION INQUIRY WRITTEN
Sep 25, 2013 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Sep 19, 2013 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 14, 2013 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 14, 2013 GNSL
SUSPENSION LETTER WRITTEN
Mar 14, 2013 CNSL
EXAMINER'S AMENDMENT ENTERED
Mar 7, 2013 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 7, 2013 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 7, 2013 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 7, 2013 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 31, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 31, 2013 CRFA
ASSIGNED TO LIE
Jan 24, 2013 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 22, 2013 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 22, 2013 TCCA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 22, 2012 GNRN
NON-FINAL ACTION E-MAILED
Jul 22, 2012 GNRT
NON-FINAL ACTION WRITTEN
Jul 22, 2012 CNRT
ASSIGNED TO EXAMINER
Jul 10, 2012 DOCK
NOTICE OF DESIGN SEARCH CODE MAILED
Apr 5, 2012 MDSM
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 4, 2012 NWOS
NEW APPLICATION ENTERED
Apr 2, 2012 NWAP